|
| ID |
DDInter1657 |
| Drug Type |
small molecule |
| Molecular Formula |
C17H11F6N7O |
| Molecular Weight |
443.311
|
| Description |
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. It is currently approved for the treatment of multiple myeloma, a cancer which forms from antibody-producing plasma cells.[L7117,L7120] This condition is typically treated with high dose [bortezomib] and dexamethasone chemotherapy followed by autologous stem-cell transplant. Other chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant.[L7123] Selinexor was approved by the FDA in June 2019. It was granted fast track and orphan designation as well as accelerated approval based on single arm, open label trial data. The Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON) trial is planned to finish in 2020.[L7126]
|
| ATC Classification |
L01XX66
|
| IUPAC Name |
(2Z)-3-{3-[3,5-Bis(Trifluoromethyl)Phenyl]-1H-1,2,4-Triazol-1-Yl}-N'-(Pyrazin-2-Yl)Prop-2-Enehydrazide |
| InChI |
Inchi=1S/C17H11F6N7O/C18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/H1-9H,(H,25,27)(H,28,31)/B4-1- |
| InChI Key |
DEVSOMFAQLZNKR-RJRFIUFISA-N |
| Canonical SMILES |
FC(F)(F)C1=CC(=CC(=C1)C1=NN(\C=C/C(=O)NNC2=NC=CN=C2)C=N1)C(F)(F)F |
| Useful Links |
DrugBank
ChEMBL
PubChem
|